Literature DB >> 19909990

Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury.

Ashish K Sharma1, Victor E Laubach, Susan I Ramos, Yunge Zhao, George Stukenborg, Joel Linden, Irving L Kron, Zequan Yang.   

Abstract

OBJECTIVE: Adenosine A(2A) receptor activation potently attenuates lung ischemia-reperfusion injury. This study tests the hypothesis that adenosine A(2A) receptor activation attenuates ischemia-reperfusion injury by inhibiting CD4+ T cell activation and subsequent neutrophil infiltration.
METHODS: An in vivo model of lung ischemia-reperfusion injury was used. C57BL/6 mice were assigned to either sham group (left thoracotomy) or 7 study groups that underwent ischemia-reperfusion (1 hour of left hilar occlusion plus 2 hours of reperfusion). ATL313, a selective adenosine A(2A) receptor agonist, was administered 5 minutes before reperfusion with or without antibody depletion of neutrophils or CD4+ T cells. After reperfusion, the following was measured: pulmonary function using an isolated, buffer-perfused lung system, T cell infiltration by immunohistochemistry, myeloperoxidase and proinflammatory cytokine/chemokine levels in bronchoalveolar lavage fluid, lung wet/dry weight, and microvascular permeability.
RESULTS: ATL313 significantly improved pulmonary function and reduced edema and microvascular permeability after ischemia-reperfusion compared with control. Immunohistochemistry and myeloperoxidase content demonstrated significantly reduced infiltration of neutrophils and CD4+ T cells after ischemia-reperfusion in ATL313-treated mice. Although CD4+ T cell-depleted and neutrophil-depleted mice displayed significantly reduced lung injury, no additional protection occurred when ATL313 was administered to these mice. Expression of tumor necrosis factor-alpha, interleukin 17, KC, monocyte chemotactic protein-1, macrophage inflammatory protein-1, and RANTES were significantly reduced in neutrophil- and CD4+ T cell-depleted mice and reduced further by ATL313 only in neutrophil-depleted mice.
CONCLUSIONS: These results demonstrate that CD4+ T cells play a key role in mediating lung inflammation after ischemia-reperfusion. ATL313 likely exerts its protective effect largely through activation of adenosine A(2A) receptors on CD4+ T cells and neutrophils. 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19909990      PMCID: PMC2813368          DOI: 10.1016/j.jtcvs.2009.08.033

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  24 in total

1.  Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage.

Authors:  A Ohta; M Sitkovsky
Journal:  Nature       Date:  2001 Dec 20-27       Impact factor: 49.962

2.  Lung transplant reperfusion injury involves pulmonary macrophages and circulating leukocytes in a biphasic response.

Authors:  S M Fiser; C G Tribble; S M Long; A K Kaza; J T Cope; V E Laubach; J A Kern; I L Kron
Journal:  J Thorac Cardiovasc Surg       Date:  2001-06       Impact factor: 5.209

3.  Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells.

Authors:  M Koshiba; H Kojima; S Huang; S Apasov; M V Sitkovsky
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

4.  Adenosine A2 receptor function in rat ventricular myocytes.

Authors:  J G Dobson; R A Fenton
Journal:  Cardiovasc Res       Date:  1997-05       Impact factor: 10.787

5.  Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation.

Authors:  N Harada; K Okajima; K Murakami; S Usune; C Sato; K Ohshima; T Katsuragi
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

Review 6.  Interleukin-17 family members and inflammation.

Authors:  Jay K Kolls; Anders Lindén
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

7.  Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells.

Authors:  Yuan-Ji Day; Liping Huang; Marcia J McDuffie; Diane L Rosin; Hong Ye; Jiang-Fan Chen; Michael A Schwarzschild; J Stephen Fink; Joel Linden; Mark D Okusa
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

8.  IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger.

Authors:  Stephane Ferretti; Olivier Bonneau; Gerald R Dubois; Carol E Jones; Alexandre Trifilieff
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

9.  Recipient T cells mediate reperfusion injury after lung transplantation in the rat.

Authors:  Marc de Perrot; Kevin Young; Yumiko Imai; Mingyao Liu; Thomas K Waddell; Stefan Fischer; Li Zhang; Shaf Keshavjee
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

10.  CD4+ T lymphocytes mediate acute pulmonary ischemia-reperfusion injury.

Authors:  Zequan Yang; Ashish K Sharma; Joel Linden; Irving L Kron; Victor E Laubach
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03       Impact factor: 5.209

View more
  36 in total

1.  Identification of hypoxia-inducible factor HIF-1A as transcriptional regulator of the A2B adenosine receptor during acute lung injury.

Authors:  Tobias Eckle; Emily M Kewley; Kelley S Brodsky; Eunyoung Tak; Stephanie Bonney; Merit Gobel; Devon Anderson; Louise E Glover; Ann K Riegel; Sean P Colgan; Holger K Eltzschig
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

Review 2.  Role of blood cells in ischaemia-reperfusion induced endothelial barrier failure.

Authors:  Stephen F Rodrigues; D Neil Granger
Journal:  Cardiovasc Res       Date:  2010-03-17       Impact factor: 10.787

3.  CD73-generated adenosine is critical for immune regulation during Toxoplasma gondii infection.

Authors:  Deeqa A Mahamed; Leon E Toussaint; Margaret S Bynoe
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

4.  The immunosuppressive role of adenosine A2A receptors in ischemia reperfusion injury and islet transplantation.

Authors:  Preeti Chhabra; Joel Linden; Peter Lobo; Mark Douglas Okusa; Kenneth Lewis Brayman
Journal:  Curr Diabetes Rev       Date:  2012-11

5.  Adenosine A3 receptor activation attenuates lung ischemia-reperfusion injury.

Authors:  Daniel P Mulloy; Ashish K Sharma; Lucas G Fernandez; Yunge Zhao; Christine L Lau; Irving L Kron; Victor E Laubach
Journal:  Ann Thorac Surg       Date:  2013-03-28       Impact factor: 4.330

Review 6.  Purinergic regulation of the immune system.

Authors:  Caglar Cekic; Joel Linden
Journal:  Nat Rev Immunol       Date:  2016-03       Impact factor: 53.106

7.  Adenosine A₂A agonist improves lung function during ex vivo lung perfusion.

Authors:  Abbas Emaminia; Damien J Lapar; Yunge Zhao; John F Steidle; David A Harris; Victor E Laubach; Joel Linden; Irving L Kron; Christine L Lau
Journal:  Ann Thorac Surg       Date:  2011-10-31       Impact factor: 4.330

8.  Lungs donated after circulatory death and prolonged warm ischemia are transplanted successfully after enhanced ex vivo lung perfusion using adenosine A2B receptor antagonism.

Authors:  Eric J Charles; J Hunter Mehaffey; Ashish K Sharma; Yunge Zhao; Mark H Stoler; James M Isbell; Christine L Lau; Curtis G Tribble; Victor E Laubach; Irving L Kron
Journal:  J Thorac Cardiovasc Surg       Date:  2017-04-12       Impact factor: 5.209

9.  Pretreatment strategy with adenosine A2A receptor agonist attenuates reperfusion injury in a preclinical porcine lung transplantation model.

Authors:  Damien J LaPar; Victor E Laubach; Abbas Emaminia; Ivan K Crosby; Vanessa A Hajzus; Ashish K Sharma; Heather M Sumner; David V Webb; Christine L Lau; Irving L Kron
Journal:  J Thorac Cardiovasc Surg       Date:  2011-07-16       Impact factor: 5.209

Review 10.  Ischemia/Reperfusion.

Authors:  Theodore Kalogeris; Christopher P Baines; Maike Krenz; Ronald J Korthuis
Journal:  Compr Physiol       Date:  2016-12-06       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.